New Hypertension Drug Trial Results Have Been Released
A new medication has shown potential for lowering blood pressure in patients with uncontrolled hypertension and sleep apnea.
Updated on Oct. 10, 2026 in Sleep Disorders
Live Poll
Do you believe pharmaceutical innovation is the most effective approach for managing chronic health conditions?
Mineralys Therapeutics recently reported positive results from clinical trials for the drug lorundrostat. The study investigated the medication's effectiveness in patients struggling with treatment-resistant hypertension and obstructive sleep apnea.
Why it matters
Uncontrolled hypertension remains a critical health challenge, contributing to 685,000 deaths in the United States in 2022. These findings offer a potential new approach for patients whose blood pressure does not respond to standard interventions.
In the Launch-HTN trial, 46% of participants receiving 50 mg of lorundrostat reached systolic blood pressure targets below 130 mmHg, while 70% saw reductions of at least 10 mmHg. The Explore-OSA trial observed a 11.1 mmHg morning systolic reduction at four weeks.
The players
Mineralys Therapeutics
A Radnor, Pennsylvania-based biopharmaceutical company focused on developing therapies for hypertension and related conditions.
The details
Lorundrostat is designed to address hypertension driven by dysregulated aldosterone levels in the body. In the clinical trials, researchers utilized automated office blood pressure monitoring for Launch-HTN and continuous overnight polysomnography to measure morning pressure changes in the Explore-OSA cohort. Notably, while the drug impacted blood pressure readings, the Explore-OSA trial showed no measurable change in apnea-hypopnea indices.
Timeline
2019: The annual economic burden of hypertension reached $219 billion in the United States.
2022: Hypertension-related issues were involved in 685,000 deaths in the United States.
Week 4: Participants in the Explore-OSA trial saw a 11.1 mmHg morning systolic blood pressure reduction.
Week 12: This served as the primary measurement point for systolic blood pressure in the Launch-HTN trial.
Health Landscape
This development represents a progression in the clinical development pipeline for aldosterone synthase inhibitors, which aim to provide alternatives for resistant hypertension. It sits alongside broader efforts to manage the $150 billion annual cost of untreated sleep apnea in the United States.
If you are managing treatment-resistant hypertension, these findings may be worth discussing with your doctor to understand how new research on aldosterone regulation could eventually impact your care. Always consult your physician before making any changes to your current blood pressure regimen.
The takeaway
These trial results highlight the ongoing research into targeted treatments for hypertension that is resistant to standard care. Tracking your blood pressure consistently and discussing resistant readings with your primary care provider remains a crucial step in long-term heart health management.
Further reading
For more on managing symptoms and cardiovascular risks, visit our Sleep Disorders section.
More information
Review the latest company reports and trial data on the Mineralys Therapeutics corporate website.
Live Poll
Do you believe pharmaceutical innovation is the most effective approach for managing chronic health conditions?
